259 related articles for article (PubMed ID: 26068927)
1. The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults.
Mendell J; Chen S; He L; Desai M; Parasramupria DA
Clin Drug Investig; 2015 Jul; 35(7):447-53. PubMed ID: 26068927
[TBL] [Abstract][Full Text] [Related]
2. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
Parasrampuria DA; Mendell J; Shi M; Matsushima N; Zahir H; Truitt K
Br J Clin Pharmacol; 2016 Dec; 82(6):1591-1600. PubMed ID: 27530188
[TBL] [Abstract][Full Text] [Related]
3. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics.
Mendell J; Johnson L; Chen S
J Clin Pharmacol; 2015 Dec; 55(12):1395-405. PubMed ID: 26011596
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects.
Parasrampuria DA; Weilert D; Maa JF; Dishy V; Kochan J; Shi M; Brown KS
Clin Drug Investig; 2016 Feb; 36(2):127-36. PubMed ID: 26597179
[TBL] [Abstract][Full Text] [Related]
5. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays.
Hillarp A; Strandberg K; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Lindahl TL
Scand J Clin Lab Invest; 2018; 78(7-8):575-583. PubMed ID: 30278787
[TBL] [Abstract][Full Text] [Related]
6. A single and multiple postprandial dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban in healthy Chinese volunteers
.
Chen X; Liu D; Wu Y; Liu Y; Song H; Jiang J; Hu P
Int J Clin Pharmacol Ther; 2017 Mar; 55(3):256-263. PubMed ID: 28025966
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.
Parasrampuria DA; Truitt KE
Clin Pharmacokinet; 2016 Jun; 55(6):641-55. PubMed ID: 26620048
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
Parasrampuria DA; Marbury T; Matsushima N; Chen S; Wickremasingha PK; He L; Dishy V; Brown KS
Thromb Haemost; 2015 Apr; 113(4):719-27. PubMed ID: 25566930
[TBL] [Abstract][Full Text] [Related]
9. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.
Mendell J; Lee F; Chen S; Worland V; Shi M; Samama MM
J Cardiovasc Pharmacol; 2013 Aug; 62(2):212-21. PubMed ID: 23615159
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination.
Mendell J; Noveck RJ; Shi M
J Cardiovasc Pharmacol; 2012 Oct; 60(4):335-41. PubMed ID: 23064240
[TBL] [Abstract][Full Text] [Related]
11. A single-dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban at 30-90 mg in healthy Chinese volunteers.
Chen X; Liu D; Wu Y; Song H; Liu Y; Jiang J; Hu P
Xenobiotica; 2017 Jul; 47(7):592-599. PubMed ID: 27560456
[TBL] [Abstract][Full Text] [Related]
12. An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults.
Duchin K; Duggal A; Atiee GJ; Kidokoro M; Takatani T; Shipitofsky NL; He L; Zhang G; Kakkar T
Clin Pharmacokinet; 2018 Feb; 57(2):221-228. PubMed ID: 28512699
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study.
Jönsson S; Simonsson US; Miller R; Karlsson MO
J Clin Pharmacol; 2015 Nov; 55(11):1268-79. PubMed ID: 25966665
[TBL] [Abstract][Full Text] [Related]
14. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.
Mendell J; Zahir H; Matsushima N; Noveck R; Lee F; Chen S; Zhang G; Shi M
Am J Cardiovasc Drugs; 2013 Oct; 13(5):331-42. PubMed ID: 23784266
[TBL] [Abstract][Full Text] [Related]
15. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
Ogata K; Mendell-Harary J; Tachibana M; Masumoto H; Oguma T; Kojima M; Kunitada S
J Clin Pharmacol; 2010 Jul; 50(7):743-53. PubMed ID: 20081065
[TBL] [Abstract][Full Text] [Related]
16. Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay.
Morishima Y; Kamisato C
Am J Clin Pathol; 2015 Feb; 143(2):241-7. PubMed ID: 25596250
[TBL] [Abstract][Full Text] [Related]
17. Edoxaban: a focused review of its clinical pharmacology.
Lip GY; Agnelli G
Eur Heart J; 2014 Jul; 35(28):1844-55. PubMed ID: 24810388
[TBL] [Abstract][Full Text] [Related]
18. Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa.
Vakkalagadda B; Frost C; Byon W; Boyd RA; Wang J; Zhang D; Yu Z; Dias C; Shenker A; LaCreta F
Am J Cardiovasc Drugs; 2016 Apr; 16(2):119-27. PubMed ID: 26749408
[TBL] [Abstract][Full Text] [Related]
19. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
Samama MM; Kunitada S; Oursin A; Depasse F; Heptinstall S
Thromb Res; 2010 Oct; 126(4):e286-93. PubMed ID: 20807664
[TBL] [Abstract][Full Text] [Related]
20. Importance of measuring pharmacologically active metabolites of edoxaban: development and validation of an ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method.
Siriez R; Alpan L; Elasaad K; Devel P; Laloy J; Dogné JM; Douxfils J
J Thromb Thrombolysis; 2020 Apr; 49(3):395-403. PubMed ID: 31925664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
